A Performance Review and Analysts’ Ratings for Celgene in May
In 1Q18, Celgene’s (CELG) Idhifa generated revenue of $14 million. Celgene and bluebird bio will commercialize the drug in the US market and share 50% of US expenditure and profits. Of the 31 analysts tracking Celgene (CELG) in May, seven analysts have recommended “strong buys,” while nine have recommended “buys” on its stock.